Skip to content
Screener

Novanta NOVT Restructuring Charges And Acquisition Related Costs

Restructuring Charges And Acquisition Related Costs at other companies

Pfizer logo
PfizerPFE
$457M+2,639%
Tenet Healthcare logo
Tenet HealthcareTHC
$31M+29.2%
Tenet Healthcare logo
Tenet HealthcareTHC
$31M+29.2%
Zoetis logo
ZoetisZTS
$77M+157%
DCH
DauchDCH
$49.8M+202%
DCH
DauchDCH
$49.8M+202%

Other financials

Income statement

See full
Revenue$265.8M+10.3%
Gross profit$120.9M+13.3%
Operating income$18.1M+21.1%
Net income$12.5M+179%
EPS (diluted)$0.30+150%

Balance sheet

See full
Cash & equivalents$718.7M+554%
Total debt$285.6M-44.5%
Total equity$1.6B+102%
Total assets$2.1B+41.6%

Cash flow

See full
Operating cash flow$64.9M+331%
CapEx$7.5M+120%
Free cash flow$57.5M+392%

Valuation

See full
Market cap$5.82B+42.2%
Enterprise value$5.38B+19.7%
P/E94.2×+27.5×
P/S5.7×+1.4×

Profitability

See full
Gross margin44.5%-0.2pp
Operating margin9%-2.2pp
Net margin6%-0.4pp
FCF margin11.1%-1.2pp

Returns & leverage

See full
Return on equity5.1%-3.1pp
Debt / equity0.2×-0.5×
Current ratio4.6×+2.0×

Where this comes from

Reported directly by Novanta in its filing.

Tagged under the XBRL concept novt:RestructuringChargesAndAcquisitionRelatedCosts.

The source filing: Novanta’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335404
Line itemThree Months Ended / July 3, 2026Three Months Ended / June 27, 2025Six Months Ended / July 3, 2026Six Months Ended / June 27, 2025
Research and development and engineering23,96825,28947,21948,527
Selling, general and administrative59,97247,103114,38192,699
Amortization of purchased intangible assets6,4156,87112,18912,425
Restructuring, acquisition, and related costs12,49912,57215,10410,117
Total operating expenses102,85491,835188,893163,768
Operating income18,06114,91145,60047,332
Interest income (expense), net(1,106)(5,815)(2,949)(11,459)
Foreign exchange transaction gains (losses), net(801)(2,744)(70)(3,112)

Item 1. Financial Statements

FAQ

What is Novanta's restructuring charges and acquisition related costs?
Novanta (NOVT) reported restructuring charges and acquisition related costs of $12.5M in Q2 2026.
How has Novanta's restructuring charges and acquisition related costs changed year-over-year?
Novanta's restructuring charges and acquisition related costs decreased by 0.6% year-over-year, from $12.57M to $12.5M.
What is the long-term trend for Novanta's restructuring charges and acquisition related costs?
Over 4 years (2021 to 2025), Novanta's restructuring charges and acquisition related costs has grown at a 5.9% compound annual growth rate (CAGR), from $18.02M to $22.65M.
What does restructuring charges and acquisition related costs mean?
This metric represents non-recurring expenses incurred from organizational restructuring initiatives and costs associated with the integration of acquired businesses. It captures the financial impact of strategic shifts, such as workforce reductions, facility consolidations, or professional fees related to mergers and acquisitions. Investors monitor this figure to distinguish between core operational performance and one-time costs that do not reflect the ongoing profitability of the business.

Ask your AI about Novanta's restructuring charges and acquisition related costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude